18Dec Pirfenidone | Horizonscan geneesmiddelen Posted by: admin Categories: Idiopathic Pulmonary Fibrosis Comments Off on Pirfenidone | Horizonscan geneesmiddelen Pirfenidone | Horizonscan geneesmiddelen www.horizonscan.nl gebruikt cookies om het gebruik van de website te analyseren en het gebruiksgemak te verbeteren. Lees meer over cookies op www.rijkshuisstijl.nlSluiten Extended indication Extension of indication to include the treatment of unclassifiable interstitial lung disease (UILD) for Esbrie. Therapeutic value No estimate possible yet Registration phase No registration expected Table of Contents Product Registration Therapeutic value Expected patient volume per year Expected cost per patient per year Potential total cost per year Off label use Indication extension Other information Product Active substance Pirfenidone Domain Lung diseases Reason of inclusion Indication extension Main indication Lung diseases other Extended indication Extension of indication to include the treatment of unclassifiable interstitial lung disease (UILD) for Esbrie. Proprietary name Esbriet Manufacturer Roche Mechanism of action Other, see general comments Route of administration Oral Therapeutical formulation Tablet Budgetting framework Intermural (MSZ) Registration Registration route Centralised (EMA) Submission date January 2021 Orphan drug Yes Registration phase No registration expected Therapeutic value Therapeutic value No estimate possible yet Expected patient volume per year There is currently nothing known about the expected patient volume. Expected cost per patient per year There is currently nothing known about the expected cost. Potential total cost per year There is currently nothing known about the possible total cost. Off label use There is currently nothing known about off label use. Indication extension There is currently nothing known about indication extensions. Other information There is currently no futher information available. Naar boven Source link